Clinical Trials at Sentara Neurosciences Institute

At Sentara, we are committed to improving the lives of patients with neurological disorders. We know that having access to cutting edge trials and research studies focuses on finding new treatments are an important part of patient care.

For more information on these clinical trials and studies, please contact our Clinical Research Coordinator at 877-310-8713.

Clinical Research Studies at Sentara Neurosciences Institute

Learn more about our ongoing research studies in the following areas:

  • Advanced Parkinson’s Disease

    Current research studies at Sentara focusing on advanced Parkinson’s disease include:

    • A current clinical research study at Sentara Princess Anne Hospital will evaluate the effectiveness of an investigational drug compared to placebo (substance that has no therapeutic effect) in decreasing motor fluctuations.
    • A clinical research study to evaluate the safety and effectiveness of an investigational medication compared to placebo (an inactive substance) in individuals with Parkinson's Disease who are experiencing hallucinations or delusions. The caregivers of participants with Parkinson's Disease and hallucinations or delusions, also play role in this study as their input is valuable. Individuals who wish to
      participate must have experienced hallucinations or delusions for at least the past month.
  • Alzheimer's Disease

    Sentara is offering a Clinical Trial evaluating the effectiveness of an Investigational medication to slow the disease progression in early stages of Alzheimer’s disease.

    Contact Information: 757-252-9026

    For more detailed information this trial may be found on www.clinicaltrials.gov using the following “title” in the Search field:

    A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

  • Atherothrombotic Ischemic Events

    Current research studies at Sentara focusing on atherothrombotic Ischemic events include:

    • Patients who have blockage in one or more arteries supplying blood to the heart, brain or legs can enroll in a study on secondary prevention of atherothrombotic Ischemic events. The study focuses on investigational drug that has not been approved for use by the health authorities or the U.S. Food and Drug Administration (FDA). The drug blocks platelets and may reduce the risk of heart attack or stroke. The purpose of the study is to test the safety and effectiveness of the drug, when used with standard medications. Such blockages are most commonly due to cholesterol deposits associated with atherosclerosis.
  • Arteriovenous Malformations (AVM)

    Current research studies at Sentara focusing on arteriovenous malformations include:

    • A National Institutes of Health sponsored study to determine whether it is better to treat an unruptured brain arteriovenous malformation (AVM) with one or more of several available procedures intended to eliminate the brain AVM or to rely on medical therapy to control symptoms.
  • Epilepsy

    Current research studies at Sentara focusing on epilepsy include:

    • An investigational intranasal medication (USL261) is being studied in outpatients with partial or generalized epilepsy as a "rescue therapy" for the treatment of seizure clusters
    • An 18-week study with patients who experience partial onset seizures and have had success with current anti-epileptic drugs (AEDs). The 18-week double-blind treatment period consists of a 2-week titration period, 6-week taper or conversion period, and a 10-week monotherapy period.

    Sentara is also offering a clinical trial to evaluate visual fields in subjects with partial epilepsy receiving 12 weeks of treatment of Lyrica compared to placebo.

    Contact Information: 757-252-9026

    For more detailed information this trial may be found on www.clinicaltrials.gov using the following “title” in the Search field:

    PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO

  • Migraine

    Sentara Neurology Specialists is currently enrolling patients with migraines. 

    1. A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE
    2. MULTICENTER, RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

    For more detailed information please visit www.clinicaltrials.gov using the “title” of the study in the Search field. To check potential eligibility and learn more about these trials, please contact 757-507-0607.

  • Mild Cognitive Impairment

    Sentara is offering a clinical trial to examine how brain imaging (PET scan) helps guide your doctors in how to treat your mild cognitive impairment or dementia. Medicare must be your primary medical coverage. The research component is to study if the brain imaging will help your doctor treat you and benefit your health; the brain imaging itself is not part of the research, but a procedure recommended by your doctor as part of clinical care.

    Contact Information: 757-252-9026

    For more detailed information this trial may be found on www.clinicaltrials.gov using the following “title” in the Search field:

    The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will establish an open-label, longitudinal cohort study to assess the impact of amyloid PET on patient outcomes.

  • Multiple Sclerosis

    Sentara Neurology Specialists is currently enrolling patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis.

    1. A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    2. A long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy
    3. A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
    4. A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
    5. A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy

    For more detailed information please visit www.clinicaltrials.gov using the “title” of the study in the Search field.  To check potential eligibility and learn more about these trials, please contact 757-507-0607.

  • Parkinson's Disease (Newly Diagnosed)

    Sentara Neurology Specialists is currently enrolling newly diagnosed Parkinson’s Disease patients not yet on Parkinson’s medication for trials aimed at slowing the progression of the disease and looking at a new form of symptomatic therapy.

    To check potential eligibility and learn more about these trials, contact 757-507-0642.

  • Parkinson's Disease (Patients with Off Time)

    Sentara Neurology Specialists is currently enrolling Parkinson’s patients that are experiencing off time with levodopa dosing.

    To check potential eligibility and learn more about these trials, please contact 757-507-0642.

  • Stroke Treatment

    Current research studies at Sentara focusing on stroke treatment include:

    • A study on insulin resistance intervention (IRIS) after stroke, sponsored by the National Institutes of Health, is examining a new therapeutic approach for stroke patients based on the detection and treatment of insulin resistance. Insulin resistance affects almost all patients with type II diabetes and 50 percent of non-diabetic patients with ischemic stroke. The IRIS trial will determine the effectiveness of a drug called pioglitazone, an agent used to reduce insulin resistance, for reducing the risk of stroke or MI (myocardial infarction or heart attack) among patients with a recent ischemic stroke or TIA (transient ischemic attack).

Sentara in the Community